Overview
- The company announced on Tuesday that it has agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Company in transactions worth up to about $3.8–$3.83 billion in cash, with each deal made of an undisclosed upfront payment plus contingent milestone payments.
- All three agreements are subject to customary closing steps, including the Hart-Scott-Rodino antitrust waiting period, and Lilly has said it will advance Curevo’s shingles program toward Phase 3 while supporting LimmaTech’s Phase 1 bacterial vaccine work and Vaccine Company’s Phase 1–ready Epstein-Barr Virus candidate after closing.
- Curevo’s lead candidate, amezosvatein, showed Phase 2 data that matched the immune response of the current shingles standard while cutting moderate-to-severe side effects by more than half, which Lilly says could improve vaccine uptake; LimmaTech targets bacterial threats such as Staphylococcus aureus and gonorrhea; Vaccine Company uses an in vivo nanoparticle platform for a five‑antigen EBV shot.
- Investors gave a modest vote of confidence with Lilly shares edging higher on the news, and Lilly framed the buys as part of a deliberate prevention strategy paid for by strong cash flow from its GLP‑1 diabetes and obesity drugs.
- The deals extend Lilly’s aggressive 2026 acquisition run but face clinical, regulatory, commercial, and public‑acceptance risks for early and mid‑stage vaccine programs and will only affect patients if the candidates clear the full development and approval pathway.